www.technologyreview.com
Open in
urlscan Pro
192.0.66.184
Public Scan
Submitted URL: https://ter.li/6q4bzf
Effective URL: https://www.technologyreview.com/2023/08/31/1078728/biotech-dopamine-making-cells-into-peoples-brains/?utm_source=engagement_emai...
Submission: On November 28 via api from US — Scanned from US
Effective URL: https://www.technologyreview.com/2023/08/31/1078728/biotech-dopamine-making-cells-into-peoples-brains/?utm_source=engagement_emai...
Submission: On November 28 via api from US — Scanned from US
Form analysis 1 forms found in the DOM
<form class="stayConnected__form--18307598e0857e3bb696e62099890f3d"><label for="email" class="stayConnected__formWrap--bc55a4930c54f6e27130718c8abe7f9f">
<div class="stayConnected__labelWrap--a7bf6e431dad2248d7a5d6743face8f4"><span class="stayConnected__label--49df038d675331d33cb3be3744dc2aa4">Enter your email</span></div>
<div class="stayConnected__inputWrap--c530e7aff15a90a594ff9e4f5f5e1783"><input type="email" id="email" name="email" class="stayConnected__input--4b385ef9dfe4b3c2c6268801645e29e9" autocomplete="email" required=""><input type="text" id="name"
name="name" class="stayConnected__hp--8d4ec1df04d5951cd624f35ba9d4fbfa" tabindex="-1" autocomplete="off">
<div class="stayConnected__submitWrap--8615eaac88e0ce927745491334961b19"><button type="submit" class="stayConnected__submit--1d8dc2a487df662d908236592da5e5fa" aria-label="Submit email">
<div class="stayConnected__arrow--464ca9ee54c47630a3d460b7de7c7f71"><svg width="17" height="15" fill="none">
<path stroke="#000" d="M0 8.149h15.66M9.532 1L16 7.809l-6.468 6.468"></path>
</svg></div>
<div class="stayConnected__check--467f0ffeb06f074452e92848a7f5b816"><svg width="18" height="16" viewBox="0 0 18 16" fill="none">
<path data-name="check" d="M1 8.32502L6.5 14.2766L17 1" stroke="black"></path>
</svg></div>
</button></div>
</div><a href="/privacy/" class="stayConnected__privacyLink--cae6fca4c8d36d5ebfe832b6c2d52a88" aria-label="Read our Privacy Policy">Privacy Policy</a>
</label>
<div class="stayConnected__responseMessage--12bde8aaa78e1b908dcc7bf65887ca9f">
<div class="stayConnected__labelWrap--a7bf6e431dad2248d7a5d6743face8f4">
<p class="stayConnected__label--49df038d675331d33cb3be3744dc2aa4 stayConnected__centered--b7b09fbd037c0a7bf4fabf1d2474317a">Thank you for submitting your email!</p>
</div><a class="stayConnected__btn--220de7597843d01758713e133a307e0d" href="/newsletter-preferences?email_address=undefined">Explore more newsletters</a>
</div>
<div class="stayConnected__responseMessage--12bde8aaa78e1b908dcc7bf65887ca9f">
<div class="stayConnected__labelWrap--a7bf6e431dad2248d7a5d6743face8f4">
<p class="stayConnected__label--49df038d675331d33cb3be3744dc2aa4 stayConnected__error--a1952d4717e04c4e1ed4f70509b52342 stayConnected__errorTitle--a6c139deaa8c1fca29336ea15a098c50">It looks like something went wrong.</p>
</div>
<p class="stayConnected__errorMessage--9a73d41f2009763d9cc7f54cee45585b"> We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at
<a href="mailto:customer-service@technologyreview.com" class="stayConnected__link--35dca415e25519bea77fdb0f42df6d96">customer-service@technologyreview.com</a> with a list of newsletters you’d like to receive.</p>
</div>
</form>Text Content
You need to enable JavaScript to view this site.
Skip to Content
MIT Technology Review
* Featured
* Topics
* Newsletters
* Events
* Podcasts
Sign in
Subscribe
MIT Technology Review
* Featured
* Topics
* Newsletters
* Events
* Podcasts
Sign in
Subscribe
Biotechnology and health
A BIOTECH COMPANY SAYS IT PUT DOPAMINE-MAKING CELLS INTO PEOPLE’S BRAINS
The experiment to treat Parkinson’s is a critical early test of stem cells’
potential to tackle serious disease.
By
* Antonio Regaladoarchive page
August 31, 2023
Getty Images
In an important test for stem-cell medicine, a biotech company says implants of
lab-made neurons introduced into the brains of 12 people with Parkinson’s
disease appear to be safe and may have reduced symptoms for some of them.
The added cells should produce the neurotransmitter dopamine, a shortage of
which is what produces the devastating symptoms of Parkinson’s, including
problems moving.
“The goal is that they form synapses and talk to other cells as if they were
from the same person,” says Claire Henchcliffe, a neurologist at the University
of California, Irvine, who is one of the leaders of the study. “What’s so
interesting is that you can deliver these cells and they can start talking to
the host.”
The study is one of the largest and most costly tests yet of embryonic-stem-cell
technology, the controversial and much-hyped approach of using stem cells taken
from IVF embryos to produce replacement tissue and body parts.
The small-scale trial, whose main aim was to demonstrate the safety of the
approach, was sponsored by BlueRock Therapeutics, a subsidiary of the drug giant
Bayer. The replacement neurons were manufactured using powerful stem cells
originally sourced from a human embryo created an in vitro fertilization
procedure.
RELATED STORY
After 25 years of hype, embryonic stem cells are still waiting for their moment
Research roadblocks and political debates have delayed progress—but scientists
are inching closer to delivering a cure.
According to data presented by Henchliffe and others on August 28 at the
International Congress for Parkinson’s Disease and Movement Disorder in
Copenhagen, there are also hints that the added cells had survived and were
reducing patients’ symptoms a year after the treatment.
These clues that the transplants helped came from brain scans that showed an
increase in dopamine cells in the patients’ brains as well as a decrease in “off
time,” or the number of hours per day the volunteers felt they were
incapacitated by their symptoms.
However, outside experts expressed caution in interpreting the findings, saying
they seemed to show inconsistent effects—some of which might be due to the
placebo effect, not the treatment.
“It is encouraging that the trial has not led to any safety concerns and that
there may be some benefits,” says Roger Barker, who studies Parkinson’s disease
at the University of Cambridge. But Barker called the evidence the transplanted
cells had survived “a bit disappointing.”
Because researchers can’t see the cells directly once they are in a person’s
head, they instead track their presence by giving people a radioactive precursor
to dopamine and then watching its uptake in their brains in a PET scanner. To
Barker, these results were not so strong and he says it’s “still a bit too early
to know” whether the transplanted cells took hold and repaired the patients’
brains.
LEGAL QUESTIONS
Embryonic stem cells were first isolated in 1998 at the University of Wisconsin
from embryos made in fertility clinics. They are useful to scientists because
they can be grown in the lab and, in theory, be coaxed to form any of the 200 or
so cell types in the human body, prompting attempts to restore vision, cure
diabetes, and reverse spinal cord injury.
However, there is still no medical treatment based on embryonic stem cells,
despite billions of dollars’ worth of research by governments and companies over
two and a half decades. BlueRock’s study remains one of the key attempts to
change that.
And stem cells continue to raise delicate issues in Germany, where Bayer is
headquartered. Under Germany’s Embryo Protection Act, one of the most
restrictive such laws in the world, it’s still a crime, punishable with a prison
sentence, to derive embryonic cells from an embryo.
What is legal, in certain circumstances, is to use existing cell supplies from
abroad, so long as they were created before 2007. Seth Ettenberg, the president
and CEO of BlueRock, says the company is manufacturing neurons in the US and
that to do so it employs embryonic stem cells from the original supplies in
Wisconsin, which remain widely used.
“All the operations of BlueRock respect the high ethical and legal standards of
the German Embryo Protection Act, given that BlueRock is not conducting any
activities with human embryos,” Nuria Aiguabella Font, a Bayer spokesperson,
said in an email.
LONG HISTORY
The idea of replacing dopamine-making cells to treat Parkinson’s dates to the
1980s, when doctors tried it with fetal neurons collected after abortions. Those
studies proved equivocal. While some patients may have benefited, the
experiments generated alarming headlines after others developed “nightmarish”
side effects, like uncontrolled writhing and jerking.
Using brain cells from fetuses wasn’t just ethically dubious to some.
Researchers also became convinced such tissue was so variable and hard to obtain
that it couldn’t become a standardized treatment. “There is a history of
attempts to transplant cells or tissue fragments into brains,” says Henchcliffe.
“None ever came to fruition, and I think in the past there was a lack of
understanding of the mechanism of action, and a lack of sufficient cells of
controlled quality.”
Yet there was evidence transplanted cells could live. Post-mortem examinations
of some patients who’d been treated with fetal cells showed that the transplants
were still present many years later. “There are a whole bunch of people involved
in those fetal-cell transplants. They always wanted to find out—if you did it
right, would it work?” says Jeanne Loring, a cofounder of Aspen Neuroscience, a
stem-cell company planning to launch its own tests for Parkinson’s disease.
The discovery of embryonic stem cells is what made a more controlled test a
possibility. These cells can be multiplied and turned into dopamine-making cells
by the billions.
The initial work to manufacture such dopamine cells, as well as tests on
animals, was performed by Lorenz Studer at Columbia University. In 2016 he
became a scientific founder of BlueRock, which was initially formed as a joint
venture between Bayer and the investment company Versant Ventures
“It’s one of the first times in the field when we have had such a
well-understood and uniform product to work with,” says Henchcliffe, who was
involved in the early efforts. In 2019, Bayer took full control of the stem-cell
company in a deal valuing it at around $1 billion.
MOVEMENT DISORDER
In Parkinson’s disease, the cells that make dopamine die off, leading to
shortages of the brain chemical. That can cause tremors, rigid limbs, and a
general decrease in movement called bradykinesia. The disease is typically
slow-moving, and a drug called levodopa can control the symptoms for years. A
type of brain implant called a deep brain stimulator can also reduce symptoms.
The disease is progressive, however, and eventually, levodopa can’t control the
symptoms as well.
BLUE ROCK THERAPEUTICS
This year, the actor Michael J. Fox confided to CNN that he retired from acting
for good after he couldn’t remember his lines anymore, although that was 30
years after his diagnosis. “I’m not gonna lie. It’s getting harder,” Fox told
the network. “Every day it’s tougher.”
The promise of a cell therapy is that doctors wouldn’t just patch over symptoms
but could actually replace the broken brain networks by adding new neurons.
“The potential for regenerative medicine is not to just delay disease, but to
rebuild brain functionality,” says Ettenberg, BlueRock’s CEO. “There is a day
when we hope that people don’t think of themselves as Parkinson’s patients.”
Ettenberg says BlueRock plans to launch a larger study next year, with more
patients, in order to determine whether the treatment is working, and how well.
hide
BY ANTONIO REGALADO
SHARE
* linkedinlink opens in a new window
* twitterlink opens in a new window
* facebooklink opens in a new window
* emaillink opens in a new window
*
* POPULAR
1. This new data poisoning tool lets artists fight back against generative
AIMelissa Heikkilä
2. Everything you need to know about artificial wombsCassandra Willyard
3. Rogue superintelligence and merging with machines: Inside the mind of
OpenAI’s chief scientistWill Douglas Heaven
4. Data analytics reveal real business valueMIT Technology Review Insights
DEEP DIVE
BIOTECHNOLOGY AND HEALTH
EVERYTHING YOU NEED TO KNOW ABOUT ARTIFICIAL WOMBS
Artificial wombs are nearing human trials. But the goal is to save the littlest
preemies, not replace the uterus.
By
* Cassandra Willyardarchive page
THE BIGGEST QUESTIONS: WHAT IS DEATH?
New neuroscience is challenging our understanding of the dying process—bringing
opportunities for the living.
By
* Rachel Nuwerarchive page
SOME DEAF CHILDREN IN CHINA CAN HEAR AFTER GENE THERAPY TREATMENT
After deafness treatment, Yiyi can hear her mother and dance to the music. But
why is it so noisy at night?
By
* Antonio Regaladoarchive page
* Zeyi Yangarchive page
SCIENTISTS JUST DRAFTED AN INCREDIBLY DETAILED MAP OF THE HUMAN BRAIN
A massive suite of papers offers a high-res view of the human and non-human
primate brain.
By
* Cassandra Willyardarchive page
STAY CONNECTED
Illustration by Rose Wong
GET THE LATEST UPDATES FROM
MIT TECHNOLOGY REVIEW
Discover special offers, top stories, upcoming events, and more.
Enter your email
Privacy Policy
Thank you for submitting your email!
Explore more newsletters
It looks like something went wrong.
We’re having trouble saving your preferences. Try refreshing this page and
updating them one more time. If you continue to get this message, reach out to
us at customer-service@technologyreview.com with a list of newsletters you’d
like to receive.
THE LATEST ITERATION OF A LEGACY
Founded at the Massachusetts Institute of Technology in 1899, MIT Technology
Review is a world-renowned, independent media company whose insight, analysis,
reviews, interviews and live events explain the newest technologies and their
commercial, social and political impact.
READ ABOUT OUR HISTORY
ADVERTISE WITH MIT TECHNOLOGY REVIEW
Elevate your brand to the forefront of conversation around emerging technologies
that are radically transforming business. From event sponsorships to custom
content to visually arresting video storytelling, advertising with MIT
Technology Review creates opportunities for your brand to resonate with an
unmatched audience of technology and business elite.
ADVERTISE WITH US
© 2023 MIT Technology Review
* ABOUT
* About us
* Careers
* Custom content
* Advertise with us
* International Editions
* Republishing
* MIT News
* HELP
* Help & FAQ
* My subscription
* Editorial guidelines
* Privacy policy
* Terms of Service
* Write for us
* Contact us
* twitterlink opens in a new window
* facebooklink opens in a new window
* instagramlink opens in a new window
* rsslink opens in a new window
* linkedinlink opens in a new window
COOKIE POLICY
We use cookies to give you a more personalized browsing experience and analyze
site traffic.See our cookie policy
Accept all cookies
Cookies settings
PRIVACY PREFERENCE CENTER
When you visit any website, it may store or retrieve information on your
browser, mostly in the form of cookies. This information might be about you,
your preferences or your device and is mostly used to make the site work as you
expect it to. The information does not usually directly identify you, but it can
give you a more personalized web experience. Because we respect your right to
privacy, you can choose not to allow some types of cookies. Click on the
different category headings to find out more and change our default settings.
However, blocking some types of cookies may impact your experience of the site
and the services we are able to offer.
More information
Allow all
MANAGE CONSENT PREFERENCES
STRICTLY NECESSARY COOKIES
Always Active
These cookies are necessary for the website to function and cannot be switched
off in our systems. They are usually only set in response to actions made by you
which amount to a request for services, such as setting your privacy
preferences, logging in or filling in forms. You can set your browser to block
or alert you about these cookies, but some parts of the site will not then work.
These cookies do not store any personally identifiable information.
FUNCTIONAL COOKIES
Functional Cookies
These cookies enable the website to provide enhanced functionality and
personalisation. They may be set by us or by third party providers whose
services we have added to our pages. If you do not allow these cookies then some
or all of these services may not function properly.
PERFORMANCE COOKIES
Performance Cookies
These cookies allow us to count visits and traffic sources so we can measure and
improve the performance of our site. They help us to know which pages are the
most and least popular and see how visitors move around the site. All
information these cookies collect is aggregated and therefore anonymous. If you
do not allow these cookies we will not know when you have visited our site, and
will not be able to monitor its performance.
TARGETING COOKIES
Targeting Cookies
These cookies may be set through our site by our advertising partners. They may
be used by those companies to build a profile of your interests and show you
relevant adverts on other sites. They do not store directly personal
information, but are based on uniquely identifying your browser and internet
device. If you do not allow these cookies, you will experience less targeted
advertising.
Back Button
PERFORMANCE COOKIES
Search Icon
Filter Icon
Clear
checkbox label label
Apply Cancel
Consent Leg.Interest
checkbox label label
checkbox label label
checkbox label label
Reject all Confirm my choices